

# Yusuke Iwata

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10687696/publications.pdf>

Version: 2024-02-01

53  
papers

1,303  
citations

361413

20  
h-index

395702

33  
g-index

53  
all docs

53  
docs citations

53  
times ranked

2107  
citing authors

#	ARTICLE	IF	CITATIONS
1	Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies. <i>Molecular Psychiatry</i> , 2022, 27, 744-757.	7.9	60
2	Neuromelanin accumulation in patients with schizophrenia: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 1205-1213.	6.1	13
3	Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels. <i>Journal of Psychiatry and Neuroscience</i> , 2022, 47, E1-E10.	2.4	12
4	The effects of acute dopamine depletion on resting-state functional connectivity in healthy humans. <i>European Neuropsychopharmacology</i> , 2022, 57, 39-49.	0.7	2
5	Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. <i>Molecular Psychiatry</i> , 2022, 27, 2950-2967.	7.9	44
6	Lower striatal dopamine D2/3receptor availability in obsessive-compulsive disorder: A meta-analysis of [11C]-raclopride and [123I]-IBZM studies. <i>Journal of Obsessive-Compulsive and Related Disorders</i> , 2021, 28, 100618.	1.5	1
7	Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2021, 2, sgab006.	1.7	14
8	Measuring amphetamine-induced dopamine release in humans: A comparative meta-analysis of [ <sup>11</sup> C]-raclopride and [ <sup>11</sup> C]-PHNO studies. <i>Synapse</i> , 2021, 75, e22195.	1.2	9
9	Exploring the relationship between impaired illness awareness and visuospatial inattention in patients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2021, 136, 468-473.	3.1	4
10	Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia. <i>NeuroImage: Clinical</i> , 2021, 32, 102852.	2.7	9
11	Insight and medication adherence in schizophrenia: An analysis of the CATIE trial. <i>Neuropharmacology</i> , 2020, 168, 107634.	4.1	48
12	What proportion of striatal D2 receptors are occupied by endogenous dopamine at baseline? A meta-analysis with implications for understanding antipsychotic occupancy. <i>Neuropharmacology</i> , 2020, 163, 107591.	4.1	16
13	Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 11-22.	3.2	34
14	Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109839.	4.8	16
15	Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. <i>Journal of Psychiatric Research</i> , 2020, 124, 151-158.	3.1	31
16	DAS: The Diabetes Awareness and Insight Scale. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 189-194.	3.6	7
17	Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia. <i>European Psychiatry</i> , 2019, 61, 63-71.	0.2	12
18	Resting-state functional connectivity in treatment response and resistance in schizophrenia: A systematic review. <i>Schizophrenia Research</i> , 2019, 211, 10-20.	2.0	15

#	ARTICLE	IF	CITATIONS
19	Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2019, 208, 420-429.	2.0	32
20	Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. <i>Journal of Psychopharmacology</i> , 2019, 33, 1199-1214.	4.0	47
21	The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 89, 207-213.	4.8	5
22	A meta-analysis of transcranial direct current stimulation for schizophrenia: "œs more better?â€. <i>Journal of Psychiatric Research</i> , 2019, 110, 117-126.	3.1	40
23	Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. <i>Biological Psychiatry</i> , 2019, 85, 596-605.	1.3	94
24	OASIS: The Obesity Awareness and Insight Scale. <i>Obesity Medicine</i> , 2018, 9, 38-44.	0.9	9
25	Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study. <i>Psychiatry Research - Neuroimaging</i> , 2018, 273, 16-24.	1.8	14
26	Reduced insulin sensitivity may be related to less striatal glutamate: An 1H-MRS study in healthy non-obese humans. <i>European Neuropsychopharmacology</i> , 2018, 28, 285-296.	0.7	6
27	Neurometabolite levels in antipsychotic-naïve/free patients with schizophrenia: A systematic review and meta-analysis of 1H-MRS studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 86, 340-352.	4.8	49
28	<scp>BASIS</scp>: The blood pressure awareness and insight scale. <i>Journal of Clinical Hypertension</i> , 2018, 20, 748-756.	2.0	9
29	Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 523-530.	2.7	11
30	F230. Glutamatergic Neurometabolite Levels in Patients With Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton MRS Study. <i>Biological Psychiatry</i> , 2018, 83, S328.	1.3	2
31	The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. <i>Psychiatry Research</i> , 2018, 268, 114-122.	3.3	62
32	Reprint of OASIS "œ Obesity Awareness and Insight Scale. <i>Primary Care Diabetes</i> , 2018, 12, 371-378.	1.8	2
33	Exploring the relationship between social attachment and dopamine D <sub>2/3</sub> receptor availability in the brains of healthy humans using [ <sup>11</sup> C]-(+)-PHNO. <i>Social Neuroscience</i> , 2017, 12, 163-173.	1.3	12
34	Impaired illness awareness and leftward visuospatial inattention in schizophrenia are attributable to a common neural deficit "œ Posterior parietal hemispheric imbalance. <i>Medical Hypotheses</i> , 2017, 100, 19-22.	1.5	1
35	Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning. <i>Psychoneuroendocrinology</i> , 2017, 81, 80-87.	2.7	10
36	Trait impulsiveness is related to smaller postâ€commissural putamen volumes in males but not females. <i>European Journal of Neuroscience</i> , 2017, 46, 2253-2264.	2.6	10

#	ARTICLE	IF	CITATIONS
37	The relationship between subcortical brain volume and striatal dopamine D <sub>2/3</sub> receptor availability in healthy humans assessed with [ <sup>11</sup> C]raclopride and [ <sup>11</sup> C]α-PHNO 3.6 PET. <i>Human Brain Mapping</i> , 2017, 38, 5519-5534.		12
38	Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 747-762.	2.6	9
39	The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer's Pathology: A Brief Report. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 341-347.	2.6	4
40	Tau in Late-Life Depression: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 615-633.	2.6	23
41	Exploring personality traits related to dopamine D <sub>2/3</sub> receptor availability in striatal subregions of humans. <i>European Neuropsychopharmacology</i> , 2016, 26, 644-652.	0.7	23
42	Benzodiazepine Use Attenuates Cortical $\beta$ -Amyloid and is Not Associated with Progressive Cognitive Decline in Nondemented Elderly Adults: A Pilot Study Using F18-Florbetapir Positron Emission Tomography. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 1028-1039.	1.2	19
43	$\beta$ -Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 923-939.	1.2	15
44	Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D <sub>2/3</sub> receptor occupancy study. <i>Psychopharmacology</i> , 2016, 233, 3803-3813.	3.1	11
45	Cortical Amyloid $\beta$ Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 149-159.	2.3	38
46	The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 65, 49-53.	4.8	17
47	Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 743-754.	2.6	33
48	Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D <sub>2/3</sub> Receptors in the Ventral Striatum of Healthy Nonobese Humans. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv014-pyv014.	2.1	59
49	Lifetime History of Depression Predicts Increased Amyloid- $\beta$ Accumulation in Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 907-919.	2.6	49
50	Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data. <i>Schizophrenia Research</i> , 2015, 161, 429-433.	2.0	22
51	Dopamine D <sub>2/3</sub> receptor availability in the striatum of antipsychotic-free older patients with schizophrenia: A [ <sup>11</sup> C]-raclopride PET study. <i>Schizophrenia Research</i> , 2015, 164, 263-267.	2.0	17
52	Neuroimaging findings in treatment-resistant schizophrenia: A systematic review. <i>Schizophrenia Research</i> , 2015, 164, 164-175.	2.0	75
53	Glutamate-mediated excitotoxicity in schizophrenia: A review. <i>European Neuropsychopharmacology</i> , 2014, 24, 1591-1605.	0.7	115